Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice

Journal of Experimental Medicine

Volumn 183, Issue 3, 1996, Pages 1215-1228

  Lacerda, João F ^a   Ladanyi, Marc ^a   Louie, Diane C ^a   Fernandez, José M ^a   Papadopoulos, Esperanza B ^a   O'Reilly, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIGENS, CD; B-LYMPHOCYTES; CALLITHRIX; CELL LINE; CELL LINE, TRANSFORMED; CYTOTOXICITY, IMMUNOLOGIC; HERPESVIRUS 4, HUMAN; HLA-D ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; LYMPHOMA; MALE; MICE; MICE, SCID; RABBITS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029917128     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.3.1215     Document Type: Article

References (47)

1. Straus, S E., J.I. Cohen, G. Tosato, and J. Meier. 1992. Epstein-Barr virus infections: biology, pathogenesis and management. Ann. Intern. Med. 118:45-58.
2. Cohen, J.I. 1991. Epscein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 70:137-160.
3. Starzl, T.E., M.A. Nalesnik, K.A. Porter, M. Ho, S. Iwatsuki, B.P. Griffith, J.T. Rosenthal, T.R. Hakala, B.W. Shaw, R.L. Hardesty, et al. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1:583-587.
4. Shapiro, R.S., K. McClain, G. Frizzera, K.J. Gajl-Peczalska, J.H. Kersey, B.R. Blazar, D.C. Arthur, D.F. Patton, J.S. Greenberg, B. Burke, et al. 1988. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood. 71:1234-1243.
5. Zutter, M.M., P.J. Martin, G.E. Sale, H.M. Shulman, L. Fisher, E.D. Thomas, and D.M. Durnam. 1988. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 72:520-529.
6. Patton, D.F., C.W. Wilkowski, C.A. Hanson, R. Shapiro, K.J. Gajl-Peczalska, A.H. Filipovich, and K.L. McClain. 1990. Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation. 49:1080-1084.
7. Gratama, J.W., M.M. Zutter, J. Minarovits, M.A.P. Oosterveer, E.D. Thomas, G. Klein, and I. Ernberg. 1991. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone marrow transplant recipients. Int. J. Cancer. 47:188-192.
8. Greenberg, P.D., J.P. Klarnet, D.E. Kern, and M.A. Keever. 1988. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog. Exp. Tumor Res. 32:104-127.
9. Riddell, S.R., K.S. Watanabe, J.M. Goodrich, C.R. Li, M.E. Agha, and P.D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (Wash. DC). 257:238-242.
10. Pipadopoulos, E.B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M.H. Carabasi, H. Castro-Malaspina, B.H. Childs, A.P. Gillio, T.N. Small, et al. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders complicating allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185-1191.
11. Bourgault, I., A. Gomez, E. Gomard, and J.P. Levy. 1991. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin. Exp. Immunol. 84:501-507.
12. Lucas, K., T. Small, R.J. O'Reilly, and B. Dupont. 1994. The development of Epstein-Barr virus specific cellular immunity following allogeneic marrow transplantation. Blood. 84 98a. (Abstr.)
13. Servida, P., S. Rossini, C. Traversari, G. Ferrari, C. Bonini, N. Nobili, L. Vago, A. Faravelli, A. Vanzulli, F. Mavilio, and C Bordignon. 1993. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity in a patient affected by EBV-induced lymphoma. Blood. 82:214a. (Abstr.)
14. Rooney, C.M., C.A. Smith, C.Y.C. Ng, S. Loftin, C. Li, R A. Krance, M.K. Brenner, and H.E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 345:9-13.
15. Bosma, G.G., R.P. Custer, and M.J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature (Lond). 301:527-530.
16. Schuler, W., I.J. Weiler, A. Schuler, R.A. Phillips, N. Rosenberg, T.W. Mak, J.F. Kearney, R.P. Perry, and M.J. Bosma. 1986. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell. 46:963-972.
17. Czitrom, A.A., S. Edwards, R.A. Philhps, M.J. Bosma, P. Marrack, and J.W. Kappler. 1985. The function of antigen-presenting cells in mice with severe combined immunodeficiency. J. Immunol. 134:2276-2280.
18. Dorshkind, K., S.B. Pollack, M.J. Bosma, and R.A. Phillips. 1985. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J. Immunol. 134: 3798-3801.
19. McCune, J.M., R. Namikawa, H. Kaneshima, L.D. Shultz, M. Lieberman, and I.L. Weissman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (Wash. DC). 241: 1632-1639.
20. Mosier, D.E., R.J. Gulizia, S.M. Baird, and D.B. Wilson. 1988. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (Lond.). 335: 256-259.
21. Simpson, E., J. Farrant, and P. Chandler. 1991. Phenotypic and functional studies of human peripheral blood lymphocytes engrafted in scid mice. Immunol. Rev. 124:97-111.
22. Rowe, M., L.S. Young, J. Crocker, H. Stokes, S. Henderson, and A.B. Rickinson. 1991. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas im man. J. Exp. Med. 173:147-158.
23. Picchio, G.R., R. Kobayashi, M. Kirven, S.M. Baird, T.J. Kipps, and D.E. Mosier. 1992. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res. 52: 2468-2477.
24. Kasai, M., T. Yoneda, S. Habu, Y. Maruyama, K. Okumura, and T. Tokunaga. 1981. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (Lond.). 291:334-335.
25. Lacerda, J.F., M. Ladanyi, C. Jagiello, and R.J. O'Reilly. 1995. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human EBV-induced lymphoproliferations in xenografted C.B-17 scid/scid mice. Transplantation. In press.
26. Wu, T.C., R.B. Mann, J.I. Epstein, E. MacMahon, W.A. Lee, P. Charache, S.D. Hayward, R.J. Kurman, G.S. Hayward, and R.F. Ambinder. 1991. Abundant expression of EBER-1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am. J. Pathol. 138:1461-1469.
27. Horan, P.K., M.J. Melnicoff, B.D. Jensen, and S.E. Slezak. 1990. Fluorescent cell labeling for in vivo and in vitro cell tracking. Methods Cell Biol. 33:469-490.
28. The non-Hodgkin's Lymphoma Pathologic Classification Group. 1982. NCI sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 49:2112-2135.
29. Katz, B.Z., N. Raab-Traub, and G. Miller. 1989. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J. Infect. Dis. 160:589-598.
30. Abedi, M.R., B. Christensson, S. al-Masud, L. Hammarström, and C.I.E., Smith. 1993. Gamma-globulin modulates growth of EBV-derived B-cell tumors in SCID mice reconstituted with human lymphocytes. Int. J. Cancer. 55:824-829.
31. Durandy, A., N. Brousse, F. Rozenberg, G. de Saint Basile, A.M. Fischer, and A. Fischer. 1992. Control of human B-cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies. J. Clin. Invest. 90:945-952.
32. Garnier, J.L., M.J. Cannon, J. Chargui, J.L. Touraine, and N.R. Cooper. 1993. EBV human B-cell lymhomas in SCID mice: description of the model and study of the role of anti-CD40 and anti-CD23 monoclonal antibodies in their development. Transplant Proc. 25:1387-1388.
33. Funakoshi, S., D.L. Longo, M. Beckwith, D K. Conley, I. Tsarfaty, R.J. Armitage, W.C Fanslow, M.K. Spriggs, and W.J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood. 83:2787-2794.
34. Baiocchi, R.A., and M.A. Caligiuri. 1994. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA. 91:5577-5581.
35. Hersh, E.M., T.M. Grogan, C.Y. Funk, and C.W. Taylor. 1993. Suppression of human lymphoma development in the severe combined immune-deficiency mouse by imexon therapy. J. Immunother. 13:77-83.
36. Boyle, T.J., K.R. Berend, J.M. DiMaio, R.E. Coles, D.F. Via, and H.K. Lyerly. 1993. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery. 114:218-226.
37. - cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. Transplantation. 58:629-633.
38. Murphy, W.J., K.C. Conlon, T.J. Sayers, R.H. Wiltrout, T.C. Back, J.R. Ortaldo, and D.L. Longo. 1993. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol. 150:3634-3642.
39. Shpitz, B., C.A. Chambers, A.B. Singhal, N. Hozumi, B.J. Fernandes, C.M. Roifman, L.M. Weiner, J.C Roder, and S. Gallinger. 1994. High level functional engraftment of severe combined immunodeficiency mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J. Immunol. Methods. 169:1-15.
40. Murray, R.J., M.G. Kurilla, J.M. Brooks, W.A. Thomas, M. Rowe, E. Kieff, and A.B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-seropositive malignancies. J. Exp. Med. 176:157-168.
41. Khanna, R., S.R. Burrows, M.G. Kurilla, C.A. Jacob, I.S. Misko, T.B. Sculley, E. Kieff, and D.J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
42. Alexander, R.B., and S.A. Rosenberg. 1991. Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. J. Immunother. 10:389-397.
43. Basse, P., R.B. Herberman, U. Nannmark, B.R. Johansson, M. Hokland, K. Wasserman, and R.H. Goldfarb. 1991. Accumulation of adoptively transferred adherent lymphokine-activated killer cells in murine metastases. J. Exp. Med. 174: 479-488.
44. Wallace, P.K., L.D. Palmer, D. Perry-Lalley, E.S. Bolton, R.B. Alexander, P.K. Horan, J.C. Yang, and K.A. Muirhead. 1993. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res. 53: 2358-2367.
45. Kast, W.M., R. Offringa, P.J. Peters, A.C. Voordouw, R H. Meloen, A.J. Van Der Eb, and C.J.M. Melief. 1989. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 59:603-614.
46. Crowley, N.J., C.E Vervaert, and H.F. Seigler. 1992. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T cells. Cancer Res. 52:394-399.
47. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647-658.